Project Grant R01CA286488
Award Date 9/3/26
Completion Date 8/31/31
Dollars Obligated $549K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
St. Louis, MO 63110, USA
Similar Awards
- The National Institutes of Health National Cancer Institute awarded The Washington University $399,829 under the Cancer Treatment Research program (CFDA 93.395) on April 1, 2026, to conduct rational design of next-generation engineered T cells for enhanced cancer immunotherapy. The research addresses limited persistence of engineered T cells in cancer treatment by harnessing 4-1BB (CD137/TNFRSF9), a co-stimulatory molecule, through structure-informed protein design. Current 4-1BB chimeric...
- The National Cancer Institute awarded The Washington University $399,829 on May 13, 2026, under the Cancer Treatment Research program (CFDA 93.395) to mechanistically characterize a novel dendritic cell-based immunotherapy for solid tumors. The project will investigate how engineered dendritic cells expressing a B7H3-specific chimeric antigen receptor fused to toll-like receptor 4 signaling domains can overcome tumor immune tolerance by efficiently capturing tumor antigens and cross-priming...
- The National Institutes of Health National Cancer Institute awarded The Washington University $645,185 under the Cancer Treatment Research program (CFDA 93.395) on May 15, 2026, to develop and test a combination immunotherapy approach for glioblastoma. The recipient will conduct research on an "expand and pull" strategy combining long-acting interleukin-7 (IL-7) with oncolytic virus therapy to expand peripheral CD8+ T cells and recruit them into the glioblastoma tumor microenvironment....
- The National Cancer Institute awarded $413,339 to Cleveland Clinic Lerner College of Medicine of Case Western Reserve University on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct research on chimeric antigen receptor (CAR) T-cell therapy for lymphoma treatment. The research aligns T-cell biology with CAR architecture to enhance lymphoma therapy, addressing the limitation that durable responses are achieved in only 35–50% of lymphoma patients currently...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Washington University a Project Grant totaling $3,182,665 (Award Date: September 24, 2025; Completion Date: August 31, 2029) under the Cancer Treatment Research program (CFDA 93.395) to investigate the role of natural killer (NK) cells in immune checkpoint therapy (ICT) of cancer. The research will elucidate the mechanisms by which NK cells constrain the effectiveness of ICT, evaluate the contribution of the NKG2D...
- The National Cancer Institute awarded The Washington University $399,829 on May 14, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct research targeting TR1 to enhance the efficacy of cancer vaccines. The funded research addresses the low efficacy of neoantigen cancer vaccines by investigating how suppressive regulatory T cells, particularly type 1 regulatory CD4 T cells (TR1), impede antitumor responses. The project will elucidate the role of the EBI3 cytokine subunit...
- The National Cancer Institute awarded Mayo Clinic $685,116 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate the role of interleukin-5 (IL-5) in chimeric antigen receptor T cell immunotherapy for cancer. The project addresses treatment failure and toxicity in CAR T cell therapy, which has achieved FDA approval in relapsed or refractory hematological cancers but shows high relapse rates within two years and significant adverse effects including...
- The National Cancer Institute awarded Washington University $562,550 on July 7, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop neoantigen-based spherical nucleic acid immunotherapeutics for triple negative breast cancer. The award funds development of a patient-specific nanoparticle immunotherapeutic, termed P-SNA, through an academic-industrial partnership between FlashPoint Therapeutics and the Gillanders Laboratory at Washington University School of Medicine. The...
- The National Cancer Institute awarded The Washington University $659,087 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to support research targeting the NRF2 oxidative stress response pathway to sensitize head and neck squamous cell carcinoma (HNSCC) to immune checkpoint inhibitors. The research develops mechanistic understanding of how NRF2 pathway activation drives immune exclusion and resistance to anti-PD1 immunotherapy in HNSCC, which accounts for the sixth...
- The National Cancer Institute awarded The Washington University $532,127 on July 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to evaluate the therapeutic index of TIP1-targeted beta and alpha radioimmunotherapy for non-small cell lung cancer treatment. The project develops and compares radiolabeled TIP1-targeted antibodies conjugated with alpha- and beta-emitting radionuclides to selectively deliver radiation to NSCLC tumor cells while minimizing off-target toxicity to...